Most Read Articles
26 Dec 2017
Supplementation with omega-3 fatty acids in combination with rosuvastatin may yield significant reductions in triglycerides and nonhigh-density lipoprotein (HDL) cholesterol as compared with rosuvastatin monotherapy, according to data from the ROMANTIC (rosuvastatin-omacor in residual hypertriglyceridemia) trial.
Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
Rachel Soon, 24 Apr 2019

With recent recalls of losartan-containing products contaminated by potentially carcinogenic nitrosamines, MIMS speaks to the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for more details.

Paediatric UTI pathogens respond well to aminopenicillin, β-lactamase inhibitors

09 May 2020
Pathogens behind paediatric febrile urinary tract infections (UTIs) show a satisfactory in vitro susceptibility profile to first-line therapy with a combination of aminopenicillin and β-lactamase inhibitors (BLI), a new study has shown.

Researchers conducted a retrospective analysis of 590 children (aged 0–18 years; 66.1 percent female) with acute pyelonephritis from whom urine samples were collected, were cultured and tested positive. Antimicrobial testing was performed through agar disk diffusion.

Majority of the samples were positive for Escherichia coli (60.8 percent). Other common uropathogens were Enterococcus spp (13.3 percent), Klebsiella spp (7.0 percent), Proteus spp (5.2 percent) and Pseudomonas aeruginosa (4.2 percent).

E. coli had an 81.0 percent sensitivity to aminopenicillin/BLI. Without the BLI add-ons, sensitivity dropped to 57.1 percent. Second and third generation cephalosporins, carbapenems, quinolones and aminoglycosides proved to be even more powerful against E. coli, which was >90 percent sensitive.

Over the 10-year period from 2009 to 2018, E. coli showed an average sensitivity to aminopenicillin/BLI of 81.0 percent. Though a rapid decrease to 64.3 percent sensitivity was observed since 2014, this was not accompanied by changes in clinical response rate.

Enterococcus spp cultures were 96.8 percent sensitive to ampicillin, but resistant to cotrimoxazole in 14.9 percent. Klebsiella spp, intrinsically resistant to ampicillin, also showed a 6.1-percent resistance rate against aminopenicillin/BLI. However, Klebisiella spp showed high sensitivity to cephalosporins, carbapenems and quinolones.

Proteus spp samples were 45.9 percent resistant to cotrimoxazole and intrinsically resistant against nitrofurantoins.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
26 Dec 2017
Supplementation with omega-3 fatty acids in combination with rosuvastatin may yield significant reductions in triglycerides and nonhigh-density lipoprotein (HDL) cholesterol as compared with rosuvastatin monotherapy, according to data from the ROMANTIC (rosuvastatin-omacor in residual hypertriglyceridemia) trial.
Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
Rachel Soon, 24 Apr 2019

With recent recalls of losartan-containing products contaminated by potentially carcinogenic nitrosamines, MIMS speaks to the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for more details.